Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly

References

• Working Group Diabetes Mellitus and Cardiovascular Disease of the Spanish Society of Diabetes Diabetes mellitus and cardiovascular risk. Recommendations of the Working Group of Diabetes Mellitus and Cardiovascular Disease of the Spanish Diabetes Society 2009 Endocrinol Nutr 2010 57 220 226 20444660
   PubMedGoogle Scholar
• Mata M Antoñanzas F Tafalla M Sanz P The cost of type 2 diabetes in Spain. CODE-2 study Gac Sanit 2002 16 511 520 Spanish 12459134
   PubMedGoogle Scholar
• González P Faure E Del Castillo A Working Group for the Study of the Cost of Diabetes Cost of diabetes mellitus in Spain Med Clin (Barc) 2006 127 776 784 Spanish 17198665
   PubMed Web of Science ®Google Scholar
• Rosado Martín J Martínez López MÁ Mantilla Morató T MAPA Prevalence of diabetes in an adult population in the region of Madrid (Spain). The Madrid Cardiovascular Risk study Gac Sanit 2012 26 243 250 Spanish 22112716
   PubMed Web of Science ®Google Scholar
• Soriguer F Goday A Bosch-Comas A Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the [email protected] Study Diabetologia 2012 55 88 93 21987347
   PubMed Web of Science ®Google Scholar
• Menéndez Torre E Lafita Tejedor J Artola Menéndez S Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes. Working Group for Consensus and Clinical Guidelines of the Spanish Diabetes Society Rev Clin Esp 2011 211 147 155 Spanish 21376312
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Puigdevall Gallego V Laudo Pardos C del Río Mayor MJ Velasco Martín A New drugs for the treatment of type-2 diabetes Rev Clin Esp 2000 200 151 156 10804761
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 2008 358 2560 2572 18539916
   PubMed Web of Science ®Google Scholar
• Nathan DM Buse JB Davidson MB Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• Dejager S Schweizer A Foley JE Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus Vasc Health Risk Manag 2012 8 339 348 22661900
   PubMedGoogle Scholar
• Cai L Cai Y Lu ZJ Zhang Y Liu P The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials J Clin Pharm Ther 2012 37 386 398 22191695
   PubMed Web of Science ®Google Scholar
• Lamberts H Wood M Hofmans-Okkes IM The International Classification of Primary Care in the European Community With a Multi-Language Layer Oxford, UK Oxford University Press 1993
   Google Scholar
• World Health Organization The Anatomical Therapeutic Chemical Classification System Geneva, Switzerland World Health Organisation 1991
   Google Scholar
• Charlson ME Pompei P Ales KL Mackenzie CR A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 1987 40 373 383 3558716
   PubMedGoogle Scholar
• Weiner JP Starfield BH Steinwachs DM Mumford LM Development and application of a population-oriented measure of ambulatory care case-mix Med Care 1991 29 452 472 1902278
   PubMed Web of Science ®Google Scholar
• Thompson SG Barber JA How should cost data in pragmatic randomised trials be analysed? BMJ 2000 320 1197 1200 10784550
   PubMed Web of Science ®Google Scholar
• Sinclair A Morley JE Rodriguez-Mañas L Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes J Am Med Dir Assoc 2012 13 497 502 22748719
   PubMed Web of Science ®Google Scholar
• Halimi S Raccah D Schweizer A Dejager S Role of vildagliptin in managing type 2 diabetes mellitus in the elderly Curr Med Res Opin 2010 26 1647 1656 20441397
   PubMed Web of Science ®Google Scholar
• Gaede P Lund-Andersen H Parving HH Pedersen O Effect of a multifactorial intervention on mortality and in type 2 diabetes N Engl J Med 2008 358 580 591 18256393
   PubMed Web of Science ®Google Scholar
• Márquez Contreras E Martell Claros N Gil Guillén V Compliance Working Group of the Association of Spanish Society of Hypertension and Spanish League for the Fight Against Arterial Hypertension (SEH-LELHA) Therapeutic non-compliance with insulin in the treatment of diabetes mellitus 2 Aten Primaria 2012 44 74 81 Spanish 22018796
   PubMed Web of Science ®Google Scholar
• Cramer JA Benedict A Muszbek N Keskinaslan A Khan ZM The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review Int J Clin Pract 2008 62 76 87 17983433
   PubMed Web of Science ®Google Scholar
• Jermendy G Wittmann I Nagy L Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus Med Sci Monit 2012 18 CR72 CR77 22293880
   PubMed Web of Science ®Google Scholar
• Guillausseau PJ Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration Treat Endocrinol 2005 4 167 175 15898822
   PubMedGoogle Scholar
• Scheen AJ DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials Diabetes Metab 2012 38 89 101 22197148
   PubMed Web of Science ®Google Scholar
• Breitscheidel L Stamenitis S Dippel FW Schöffski O Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: a review paper J Med Econ 2010 13 8 15 19947905
   PubMedGoogle Scholar
• Wild H The economic rationale for adherence in the treatment of type 2 diabetes mellitus Am J Manag Care 2012 18 Suppl 3 S43 S48 22558941
   PubMedGoogle Scholar
• Liu S Zhao Y Hempe JM Fonseca V Shi L Economic burden of hypoglycaemia in patients with Type 2 diabetes Expert Rev Pharmacoecon Outcomes Res 2012 12 47 51 22280196
   PubMed Web of Science ®Google Scholar
• Stamataros G Schneider SH Vildagliptin in the treatment of type 2 diabetes mellitus Expert Opin Pharmacother 2011 12 1967 1973 21679097
   PubMed Web of Science ®Google Scholar
• Genovese S Tedeschi D Effects of vildagliptin/metformin therapy on patient-reported outcomes: work productivity, patient satisfaction, and resource utilization Adv Ther 2013 30 152 164 23430354
   PubMed Web of Science ®Google Scholar
• Strain WD Lukashevich V Kothny W Hoellinger MJ Paldánius PM Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study Lancet 2013 382 409 416 23706759
   PubMed Web of Science ®Google Scholar
• Elisabeth Müller V Schmacke N Kolip P Berger B Desirable, unfamiliar and in need of communication – the evidence-based decision aid of the Institute for Quality and Efficiency in Health Care (IQWiG) Z Evid Fortbild Qual Gesundhwes 2012 106 290 294 German 22749077
   PubMedGoogle Scholar